A phase III, multicenter, randomized, open-label, prospective, international study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation for delaying castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC).